The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes
- 511 Downloads
This study assessed the association between glucose-lowering drug (GLD) use, including metformin, sulphonylurea derivatives and insulin, after breast cancer diagnosis and breast cancer-specific and all-cause mortality. 1763 breast cancer patients, diagnosed between 1998 and 2010, with type 2 diabetes were included. Cancer information was retrieved from English cancer registries, prescription data from the UK Clinical Practice Research Datalink and mortality data from the Office of National Statistics (up to January 2012). Time-varying Cox regression models were used to calculate HRs and 95 % CIs for the association between GLD use and breast cancer-specific and all-cause mortality. In 1057 patients with diabetes before breast cancer, there was some evidence that breast cancer-specific mortality decreased with each year of metformin use (adjusted HR 0.88; 95 % CI 0.75–1.04), with a strong association seen with over 2 years of use (adjusted HR 0.47; 95 % CI 0.26–0.82). Sulphonylurea derivative use for less than 2 years was associated with increased breast cancer-specific mortality (adjusted HR 1.70; 95 % CI 1.18–2.46), but longer use was not (adjusted HR 0.94; 95 % CI 0.54–1.66). In 706 patients who developed diabetes after breast cancer, similar patterns were seen for metformin, but sulphonylurea derivative use was strongly associated with cancer-specific mortality (adjusted HR 3.64; 95 % CI 2.16–6.16), with similar estimates for short- and long-term users. This study provides some support for an inverse association between, mainly long-term, metformin use and (breast cancer-specific) mortality. In addition, sulphonylurea derivative use was associated with increased breast cancer-specific mortality, but this should be interpreted cautiously, as it could reflect selective prescribing in advanced cancer patients.
KeywordsGlucose-lowering drugs Metformin Sulphonylurea derivatives Insulin Diabetes Breast cancer
This study is based partly on data from the Clinical Practice Research Datalink, obtained under licence from the United Kingdom Medicines and Healthcare products Regulatory Agency. However, the interpretation and conclusions contained in this study are those of the authors alone.
Conflict of interest
The authors declare no conflict of interest relevant to this article.
C.R.C was supported by a United Kingdom National Institute for Health Research awarded Career Development Fellowship funded by the Health and Social Care Research and Development (Public Health Agency, Northern Ireland), which also funded access to the Clinical Practice Research Database dataset. The funders had no role in the study design; collection, analysis and interpretation of the data; writing of the report; or the decision to submit for publication.
- 2.van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR (2007) Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer 120(9):1986–1992. doi: 10.1002/ijc.22532 CrossRefPubMedGoogle Scholar
- 6.Queiroz EA, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, Barbosa AM, Dekker RF, Fortes ZB, Khaper N (2014) Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One 9(5):e98207. doi: 10.1371/journal.pone.0098207 CrossRefPubMedCentralPubMedGoogle Scholar
- 9.Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, Ipp E, Kaklamani VG, Vitolins M, Wallace R, Gunter M, Phillips LS, Strickler H, Margolis K, Euhus DM (2012) Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 30(23):2844–2852. doi: 10.1200/jco.2011.39.7505 CrossRefPubMedCentralPubMedGoogle Scholar
- 12.Oppong BA, Pharmer LA, Oskar S, Eaton A, Stempel M, Patil S, King TA (2014) The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med 3(4):1025–1034. doi: 10.1002/cam4.259
- 13.Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM (2012) Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118(5):1202–1211. doi: 10.1002/cncr.26439 CrossRefPubMedCentralPubMedGoogle Scholar
- 19.British Medical Association and the Royal Pharmaceutical Society of Great Britain (2013) British National Formulary, http://www.bnf.org/bnf/index.htm
- 21.Kirkwood BR, Sterne JAC (2003) Essential medical statistics, 2nd edn. Blackwell publishing, HobokenGoogle Scholar
- 25.Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297–3302. doi: 10.1200/jco.2009.19.6410 CrossRefPubMedCentralPubMedGoogle Scholar
- 27.Duggan C, Wang CY, Neuhouser ML, Xiao L, Smith AW, Reding KW, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R, McTiernan A (2013) Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer. Int J Cancer 132(5):1191–1200. doi: 10.1002/ijc.27753 CrossRefPubMedCentralPubMedGoogle Scholar
- 29.Goodwin P, Stambolic V, Lemieux J, Chen B, Parulekar W, Gelmon K, Hershman D, Hobday T, Ligibel J, Mayer I, Pritchard K, Whelan T, Rastogi P, Shepherd L (2011) Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126(1):215–220. doi: 10.1007/s10549-010-1224-1 CrossRefPubMedGoogle Scholar
- 30.NCIC Clinical Trials Group, National Cancer Institute, A Phase III Randomized Trial of Metformin versus Placebo in Early Stage Breast Cancer. ClinicalTrials.gov [Internet]. https://clinicaltrials.gov/ct2/show/NCT01101438. NLM Identifier: NCT01101438
- 31.Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29(2):254–258. doi: 10.2337/diacare.29.02.06.dc05-1558
- 34.Ferguson RD, Novosyadlyy R, Fierz Y, Alikhani N, Sun H, Yakar S, Leroith D (2012) Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res 14(1):R8. doi: 10.1186/bcr3089 CrossRefPubMedCentralPubMedGoogle Scholar
- 35.Perseghin G, Calori G, Lattuada G, Ragogna F, Dugnani E, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L (2012) Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol 49(6):421–428. doi: 10.1007/s00592-011-0361-2 CrossRefPubMedGoogle Scholar